Literature DB >> 33293725

Neutralizing antibodies for the treatment of COVID-19.

Shibo Jiang1,2, Xiujuan Zhang1, Yang Yang3,4, Peter J Hotez5, Lanying Du6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33293725     DOI： 10.1038/s41551-020-00660-2

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN： 2157-846X            Impact factor:   25.671


× No keyword cloud information.
  1 in total

1.  SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.

Authors:  M Jaume; M S Yip; Y W Kam; C Y Cheung; F Kien; A Roberts; P H Li; I Dutry; N Escriou; M Daeron; R Bruzzone; K Subbarao; J S M Peiris; B Nal; R Altmeyer
Journal:  Hong Kong Med J       Date:  2012-02       Impact factor: 2.227
  1 in total
  36 in total

Review 1.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.

Authors:  Lanying Du; Yang Yang; Xiujuan Zhang; Fang Li
Journal:  Nanoscale       Date:  2022-01-27       Impact factor: 7.790

2.  Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies.

Authors:  Yufei Xiang; Zhe Sang; Lirane Bitton; Jianquan Xu; Yang Liu; Dina Schneidman-Duhovny; Yi Shi
Journal:  Cell Syst       Date:  2021-02-15       Impact factor: 10.304

3.  Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2.

Authors:  Donovan Guttieres; Anthony J Sinskey; Stacy L Springs
Journal:  Antib Ther       Date:  2021-03-20

4.  Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.

Authors:  Jungsoon Lee; Zhuyun Liu; Wen-Hsiang Chen; Junfei Wei; Rakhi Kundu; Rakesh Adhikari; Joanne Altieri Rivera; Portia M Gillespie; Ulrich Strych; Bin Zhan; Peter J Hotez; Maria Elena Bottazzi
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-07       Impact factor: 4.813

Review 5.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

6.  The Immunopathobiology of SARS-CoV-2 Infection.

Authors:  Milankumar Patel; Farah Shahjin; Jacob D Cohen; Mahmudul Hasan; Jatin Machhi; Heerak Chugh; Snigdha Singh; Srijanee Das; Tanmay A Kulkarni; Jonathan Herskovitz; Douglas D Meigs; Ramesh Chandra; Kenneth S Hettie; R Lee Mosley; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  FEMS Microbiol Rev       Date:  2021-11-23       Impact factor: 16.408

7.  Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro.

Authors:  Fabrizio Pucci; Marianne Rooman
Journal:  Viruses       Date:  2021-05-18       Impact factor: 5.048

Review 8.  Pathophysiology of COVID-19-associated acute kidney injury.

Authors:  Matthieu Legrand; Samira Bell; Lui Forni; Michael Joannidis; Jay L Koyner; Kathleen Liu; Vincenzo Cantaluppi
Journal:  Nat Rev Nephrol       Date:  2021-07-05       Impact factor: 42.439

9.  Full-Length Computational Model of the SARS-CoV-2 Spike Protein and Its Implications for a Viral Membrane Fusion Mechanism.

Authors:  Wataru Nishima; Marta Kulik
Journal:  Viruses       Date:  2021-06-11       Impact factor: 5.048

10.  Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.

Authors:  Amanda J Griffin; Kyle L O'Donnell; Kyle Shifflett; John-Paul Lavik; Patrick M Russell; Michelle K Zimmerman; Ryan F Relich; Andrea Marzi
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.